Short-term clinical outcomes of ticagrelor versus clopidogrel after percutaneous coronary intervention in patients with myocardial infarction: A randomized clinical trial study

Background: Reperfusion can be done through primary percutaneous coronary intervention (PPCI) and thrombolytic administration. Patients with myocardial infarction should receive antiplatelet drugs from the P2Y12 receptor inhibitor category (such as ticagrelor, prasugrel, and clopidogrel). Based on r...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Salman Nikfarjam, Yasaman Borghei, Arsalan Salari, Seyyed Mehrad Miraftabi, Bahare Gholami-Chaboki, Seyyed Aboozar Fakhr-Moosavi
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Wolters Kluwer Medknow Publications 2023-01-01
Edice:	Research in Cardiovascular Medicine
Témata:	clopidogrel myocardial infarction percutaneous coronary intervention ticagrelor
On-line přístup:	http://www.rcvmonline.com/article.asp?issn=2251-9572;year=2023;volume=12;issue=2;spage=56;epage=60;aulast=Nikfarjam
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!